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THE few studies on the levels of
the major immunoglobulin classes (IgA,
IgG and IgM) in breast cancer patients
have yielded different results. For in-
stance, Hughes (1971) found serum IgA
levels to be no higher than those in
control subjects. Dostalova et al. (1970)
and Rowinska-Zakrewska, Lazar and Bur-
tin (1970), on the other hand, reported
raised levels of IgA, as did Roberts,
Bathgate and Stevenson (1.975) who in
addition found that IgG levels were
significantly lower. Levels of immuno-
globulin D (JgD) were apparently not
investigated in this disease.
We report here our findings in breast
cancer patients, and discuss the relation-
ship between serum immunoglobulin levels
and stage ofthe disease.
One hundred and eleven females with
breast cancer were between the age of
28 and 84 years; mean age was 57, with
a majority of cases between 45 and 69
years. All patients were staged using
clinicopathological criteria according to
the TNM classification (UICC, 1973).
The mean ages of different stages were
similar.
Blood was taken at the time of
diagnosis and before treatment. Only
patients with distant metastases had
been treated previously, and in these
cases therapy stopped at least 3 months
earlier.
Serum immunoglobulin levels were
determined by the standard (Mancini,
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Carbonara and Heremans, 1965) tech-
nique of radial immunodiffusion, using
IDP Sevac (Praha) containing swine
antisera to IgA, IgG, IgM and IgD
respectively.
Results of an extensive study of serum
immunoglobulin levels in the healthy
population of Czechoslovakia were taken
as control values (Zavaizal and Roz-
primova, 1974). For our purpose healthy
women over 40 years old were used:
half of them 40-50 years, and half 50-70
years.
Estimations of immunoglobulins in
this study were made by the same method,
using the same IDP Sevac.
Results in different cancer groups and
controls were compared and analysed
by Student's t test, with P < 0 05 as the
level of significance.
Mean immunoglobulin values are rang-
ed in the Table according to immuno-
globulin class and to the stage of the
disease.
IgA. Significantly higher levels are
found in Groups (c) and (d) than in the
controls. There is also a significant
difference between Groups (a) and (d).
IgG. There is a statistically signifi-
cant difference between Group (c) and
controls but not between other cancer
groups.
IgM.-There are no significant dif-
ferences between any of the groups.
IgD. In all cancer groups, signifi-
cantly lower levels were found than inSERUM IMMUNOGLOBULIN IN BREAST CANCER 489
TABLE.-Serum Immunoglobulin Levels in Breast Cancer Patients and Controls
Breast Number IgA: iu/ml IgG: iu/ml IgM: iu/ml IgD: iu/ml
cancer tested (mean 4 s.d.) (mean±s.d.) (mean±s.d.) (mean±s.d.)
(a) T1_2No01Mo 48 172-5±87-0 156-8±26-2 193-1±78-8 *30-1±31-2
(b) T3-4No-laMo 11 196-8±81-0 173-4±38-6 205-5±98-1 *18-0±23-3
(c) Tl12N2-3Mo 33 *204-4±101-4 *168.2+26-8 195-2±81-7 *25-6±31-6
T3-4Nlb-3Mo
(d) T1_4No-3MI 19 *246-6±108-4 173-7+39-7 206-8±113-3 *24-3±28-3
Controls 157-8±49-1 153-7±51-3 206-1±70-3 53-7±46-4
(No. testedl) (228) (172) (230) (192)
* Significant difference between cancer patients and controls.
controls, but there are no significant
differences between groups.
We are aware that clinical staging
of breast cancer is problematic. It is
established that clinical palpability, parti-
cularly with regard to nodal status,
may not always reflect the histological
picture. Nevertheless this classification
is accepted by most authors and serves
as a practical guide for experienced
specialists. Therefore the investigation
of biochemical or immunological para-
meters in relation to this staging has
some relevance.
We think that locally advanced disease
(T3-4N0M0 and T3-4NIaM0 with the
reservation mentioned above) seems to
constitute a biologically distinct group.
The tumours grow locally without ap-
parent tendency to disseminate, but it
is not clear whether this is caused by
tumour quality or by the ability of the
host to confine the tumour. We did
not therefore combine this series with
any other, despite the small number in
this classification.
We have confirmed the findings of
most authors, of raised IgA levels in
breast cancer patients. We have found
elevated levels of IgA in all stages of the
disease, which is in accordance with find-
ings of Roberts et al. (1975), who first
thoroughly discussed the staging. In
addition, we have found marked dif-
ferences between early and advanced
stages. The significance of this finding
remains unknown, and all explanations
are necessarily speculative. It is never-
34
theless of interest in relation to the
possible importance of IgA in other
types of malignant disease (Levy et
al., 1975; Brown et al., 1975; Zeromski et
al., 1975; O'Neill and Romsdahl, 1974)
and to the recent theories that immune
exclusion is a function of IgA (Stiehm,
1973; Stokes, Soothill and Turner, 1975).
Our results for IgG are, on the whole,
in agreement with most authors, who
found the levels to be normal. Although
mean IgG levels in advanced series are
elevated (in one group there is a significant
difference from the controls), most of
the results are within the normal range.
The role of 1gD in the human immune
response has not been clearly defined.
Therefore we cannot speculate at present
on the lower IgD levels found in all
stages of breast cancer patients. IgA
levels are of more importance. Meyer et
al. (1973) reported that post-mastectomy
irradiation was detrimental to patients
with a low IgA concentration, and might
improve survival in women with a high
preoperative level. Taking these findings
into account we believe that the prognostic
value of changes in IgA levels may not
be so indicative as our data might lead us
to suppose.
We thank Dr J. Bystry for help with
mathematical evaluation.
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